卵巢癌风险预测模型在上皮性卵巢癌早期诊断中的应用价值

doi:10.13481/j.1671-587x.20190428

摘要/Abstract

摘要： 目的：探讨卵巢癌风险预测模型（ROMA）对上皮性卵巢癌患病风险的评估价值及与患者临床病理分期的关联性，为上皮性卵巢癌的临床诊疗及预后分析提供依据。方法：回顾性分析经术后石蜡切片病理确诊的135例卵巢肿瘤患者的临床资料，将其分为卵巢良性肿瘤组（n=66）、上皮性卵巢癌组（n=58）和非上皮性卵巢癌组（n=11）。根据各组患者术前检测的血清人附睾蛋白4（HE4）和糖类抗原125（CA125）水平计算其ROMA值，根据各组患者HE4、CA125和ROMA临界值计算HE4、CA125和ROMA阳性率，分析卵巢癌患者血清HE4、CA125和ROMA阳性率与患者临床分期之间的关系，评价其对卵巢肿瘤患者的诊断效能。结果：上皮性卵巢癌组患者血清HE4、CA125水平和ROMA值均明显高于卵巢良性肿瘤组及非上皮性卵巢癌组（P<0.05）。上皮性卵巢癌组患者HE4、CA125和ROMA阳性率均高于卵巢良性肿瘤组（P<0.01），并随着临床分期的升高而升高。与HE4和CA125阳性率比较，卵巢良性肿瘤患者ROMA阳性率最低，在各期上皮性卵巢癌中ROMA阳性率均高于CA125阳性率。ROMA在绝经后卵巢肿瘤患者组的敏感度及阴性预测值均高于绝经前卵巢肿瘤患者组（P<0.05），而特异度及阳性预测值在绝经前及绝经后卵巢肿瘤患者组间比较差异无统计学意义（P>0.05）。3项指标中，ROMA的各项诊断效能指标最高，CA125的各项诊断效能指标最低。结论：ROMA对上皮性卵巢癌风险的诊断价值高于CA125或HE4，对绝经后患者具有更好的诊断价值，可提高卵巢癌的早期诊断效能。

关键词: 糖类抗原125, 人附睾蛋白4, 卵巢肿瘤, 卵巢癌风险预测模型, 临床诊断

Abstract: Objective:To investigate the value of risk ovarian malignancy algorithm (ROMA) in evaluation of the risk of epithelial ovarian cancer and its association with the clinical pathological stages, and to provide a basis for the clinical diagnosis and treatment and prognosis analysis of epithelial ovarian cancer. Methods:The clinical materials of 135 patients with ovarian tumor confirmed by paraffin section pathology after operation were retrospectively analyzed. The patients were divided into benign ovarian tumor group(n=66), epithelial ovarian cancer group(n=58) and non-epithelial ovarian cancer group(n=11).According to the cutoff values of HE4,CA125,and ROMA of the patients in various groups,the positive rates of HE4,CA125,and ROMA of the patients in various groups were calculated.Based on the serum levels of human epididymis protein 4(HE4) and carbohydrate antigen 125(CA125) detected before operation of the patients in various groups, the relationships between the positive rates of serum HE4, CA125 and ROMA and the clinical stages of the patients with ovarian cancer;their diagnosis efficacies in the patients with ovarian cancer were evaluated. Results:The serum CA125, HE4 levels and ROMA value of the patients in epithelial ovarian cancer group were significantly higher than those in benign ovarian tumor group and non-epithelial ovarian cancer group (P<0.05). The positive rates of HE4, CA125, and ROMA of the patients in epithelial ovarian cancer group were higher than those in benign ovarian tumor group (P<0.01), and showed an increasing trend with the increase of clinical stages.Compared with the positive rates of HE4 and CA125, the ROMA had the lowest positive rate in the patients with ovarian benign tumor, and the positive rates of ROMA in all stages of epithelial ovarian cancer were higher than those of CA125.The sensitivity and the negative predictive value of ROMA in postmenopausal patients with ovarian cancer group were higher than those in premenopausal patients with ovarian cancer group (P<0.05), while the specificity and the positive predictive value were not significantly different between premenopausal and postmenopausal patients with ovarian cancer groups (P>0.05). Among the three indexes, ROMA had the highest diagnostic efficacy index and CA125 had the lowest. Conclusion:The diagnostic value of ROMA for evaluating the risk of epithelial ovarian cancer was higher than those of CA125 and HE4, which has a better diagnostic value for the postmenopausal patients and can improve the early diagnosis efficiency of ovarian cancer.

Key words: carbohydrate antigen 125, human epididymis protein 4, ovarian neoplasms, Risk Ovarian Malignancy Algorithm, clinical diagnosis

中图分类号:

R737.31

王一品, 赫东芸, 黄琼卫, 盛敏佳. 卵巢癌风险预测模型在上皮性卵巢癌早期诊断中的应用价值[J]. 吉林大学学报(医学版), 2019, 45(04): 905-910.

WANG Yipin, HE Dongyun, HUANG Qiongwei, SHENG Minjia. Application value of risk ovarian malignancy algorithm in early diagnosis of epithelial ovarian cancer[J]. Journal of Jilin University(Medicine Edition), 2019, 45(04): 905-910.

参考文献

[1] PARYZHAK SIA, IAKUBETS' O I, VOROBETS Z D. Markers and regulatory mechanisms in ovarian carcinoma[J]. Ukr Biochem J, 2014,86(4):36-50.
[2] LU K H. Screening for ovarian cancer in asymptomatic women[J]. JAMA, 2018, 319(6):557-558.
[3] KUMARI S. Serum biomarker based algorithms in diagnosis of ovarian cancer:A review[J]. Indian J Clin Biochem, 2018,33(4):382-386.
[4] MOORE R G, MCMEEIN D S, BROWN A K, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2009,112(1):40-46.
[5] LYCKE M, KRISTJANSDOTTIR B, SUNDFELDT K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index[J]. Gynecol Oncol, 2018,151(1):159-165.
[6] CHAN K K, CHEN C A, NAM J H, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass[J]. Gynecol Oncol, 2013,128(2):239-244.
[7] ROMAGNOLO C, LEON A E, FABRICIO A S C, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass:An Italian multicenter study[J]. Gynecol Oncol, 2016,141(2):303-311.
[8] JEONG T D, CHO E J, KO D H, et al. A new strategy for calculating the risk of ovarian malignancy algorithm(ROMA)[J]. Clin Chem Lab Med, 2017,55(8):1209-1214.
[9] SANDRI M T, BOTTARI F, FRANCHI D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass:correlation with pathological outcome[J]. Gynecol Oncol, 2013,128(2):233-238.
[10] CRADIC K W, LASHO M A, ALGECIRAS-SCHIMNICH A. Validation of the cut-points recommended for ROMA using the roche elecsys CA125 and HE4 assays[J]. Ann Clin Lab Sci, 2018,48(1):90-93.
[11] HENDERSON J T, WEBBER E M, SAWAYA G F. Screening for ovarian cancer:updated evidence report and systematic review for the US preventive services task force[J]. JAMA, 2018,319(6):595-606.
[12] IONESCU C A, MATEI A, NAVOLAN D, et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses[J]. Medicine (Baltimore), 2018,97(31):e11762.
[13] YANG W L, ZHEN L, ROBERT C B. The role of biomarkers in the management of epithelial ovarian cancer[J]. Expert Rev Mol Diagn, 2017,17(6):577-591.
[14] WEI S, LI H, ZHANG B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer[J]. Biomed Rep, 2016,5(1):41-44.
[15] MOORE R G, MILLER M C, DISILVESTRO P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstet Gynecol, 2011,118(2 Pt 1):280-288.
[16] LIN J, QIN J, SANGVATANAKUL V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer:a systematic review and meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 167(1):81-85.
[17] ANTON C, CARVALHO F M, OLIVEIRA E I,et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses[J]. Clinics(Sao Paulo), 2012,67(5):437-441.
[18] SHEN F X, LU S M, PENG Y B, et al. Performance of ROMA based on Architect CA125Ⅱ and HE4 values in Chinese women presenting with a pelvic mass:A multicenter prospective study[J]. Clin Chim Acta, 2017,471:119-125.
[19] BANDIERA E, ROMANI C, SPECCHIA C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(12):2496-2506.
[20] DAYYANI F, UHLIG S, COLSON B, et al. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer:A meta-analysis[J]. Int J Gynecol Cancer, 2016,26(9):1586-1593.
[21] 冯艾,张琳,陈艳炯.不同绝经状态女性血清HE4、CA125和ROMA指数在卵巢癌诊断中的意义[J].西安交通大学学报:医学版,2018,39(1):78-83.
[22] MOLINA R,ESCUDERO J M,AUGÉ J M,et al. HE4:a novel tumour marker for ovarian cancer:comparison with CA125 and ROMA algorithm in patients with gynaecological diseases[J].Tumour Biol,2011,32(6):1087-1095.